Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Aminohippurate Sodium

FDA-approved product (injectable, injection), marketed as Aminohippurate Sodium.

Registered studies
29
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Aminohippurate Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Aminohippurate Sodium. Its therapeutic class is shown instead.

WHO therapeutic group
Tests for renal function and ureteral injuries
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Aminohippurate Sodium, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA12.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli13.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

29registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Aminohippurate Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Aminohippurate Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Renal Hemodynamics in Patients With HFpEF

    NCT03672591 · start 2018-11-30

    Registered record
    Registry ID
    NCT03672591
    Conditions
    Heart Failure With Normal Ejection Fraction
    Interventions
    Renal clearance examination
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-11-30
    Completion
    2019-06-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Normal Ejection Fraction
    InterventionRenal clearance examination
    PhaseNot recorded
    Registry statusCompleted

  • Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study

    NCT03584217 · start 2018-10-01

    Registered record
    Registry ID
    NCT03584217
    Conditions
    Type 2 Diabetes Mellitus; Obesity; Nephropathy; Adolescent Obesity
    Interventions
    Aminohippurate Sodium Inj 20%; Iohexol Inj 300 MG/ML; Renal Biopsy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2018-10-01
    Completion
    2023-10-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Obesity; Nephropathy; Adolescent Obesity
    InterventionAminohippurate Sodium Inj 20%; Iohexol Inj 300 MG/ML; Renal Biopsy
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function

    NCT03618420 · start 2018-10-01

    Registered record
    Registry ID
    NCT03618420
    Conditions
    Diabetes Mellitus, Type 1; Nephropathy; Diabetic Nephropathies; Juvenile Diabetes; Diabetes Mellitus Complication; Autoimmune Diabetes; Type 1 Diabetes Mellitus
    Interventions
    Aminohippurate Sodium Inj 20%; Iohexol Inj 300 mg/mL
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-10-01
    Completion
    2021-08-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 1; Nephropathy; Diabetic Nephropathies; Juvenile Diabetes +3 more
    InterventionAminohippurate Sodium Inj 20%; Iohexol Inj 300 mg/mL
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes

    NCT03620773 · start 2018-10-01

    Registered record
    Registry ID
    NCT03620773
    Conditions
    Type 2 Diabetes Mellitus; Obesity; Bariatric Surgery Candidate; Nephropathy; Diabetic Kidney Disease; Diabetes Mellitus, Type 2; Diabetes Mellitus; Diabetes Complications; Weight Loss; Diabetic Nephropathies; Adolescent Obesity; Pediatric Obesity
    Interventions
    Aminohippurate Sodium Inj 20%; Iohexol Inj 300 mg/mL; Vertical Sleeve Gastrectomy; Renal Biopsy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-10-01
    Completion
    2024-09-25
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Obesity; Bariatric Surgery Candidate; Nephropathy +8 more
    InterventionAminohippurate Sodium Inj 20%; Iohexol Inj 300 mg/mL; Vertical Sleeve Gastrectomy; Renal Biopsy
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Evaluation of Lysine-Specific Demethylase 1

    NCT01702688 · start 2012-07

    Registered record
    Registry ID
    NCT01702688
    Conditions
    Hypertension
    Interventions
    Para-aminohippuric Acid; Angiotensin II
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2012-07
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionPara-aminohippuric Acid; Angiotensin II
    PhaseNot applicable
    Registry statusWithdrawn

  • Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers

    NCT01156220 · start 2012-01

    Registered record
    Registry ID
    NCT01156220
    Conditions
    Healthy Male and Female Volunteers
    Interventions
    Furosemide; aminohippurate sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2012-01
    Completion
    2012-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Male and Female Volunteers
    InterventionFurosemide; aminohippurate sodium
    PhasePhase 4
    Registry statusWithdrawn

  • Caveolin-1 and Vascular Dysfunction

    NCT01426529 · start 2010-10-01

    Registered record
    Registry ID
    NCT01426529
    Conditions
    Hypertension; Insulin Resistance
    Interventions
    Para-aminohippuric Acid; Angiotensin II; Norepinephrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2010-10-01
    Completion
    2026-10-15
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Insulin Resistance
    InterventionPara-aminohippuric Acid; Angiotensin II; Norepinephrine
    PhasePhase 1
    Registry statusActive not recruiting

  • A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

    NCT01214993 · start 2010-10

    Registered record
    Registry ID
    NCT01214993
    Conditions
    Infections, Human Immunodeficiency Virus and Tuberculosis
    Interventions
    GSK1349572; Placebo; Iohexol Injection; Para-aminohippurate infusion
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-10
    Completion
    2010-11
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Human Immunodeficiency Virus and Tuberculosis
    InterventionGSK1349572; Placebo; Iohexol Injection; Para-aminohippurate infusion
    PhasePhase 1
    Registry statusCompleted

  • Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity

    NCT01241669 · start 2010-10

    Registered record
    Registry ID
    NCT01241669
    Conditions
    Healthy Subjects
    Interventions
    E5555; E5555
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-10
    Completion
    Not recorded
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionE5555; E5555
    PhasePhase 1
    Registry statusCompleted

  • Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration

    NCT01146288 · start 2010-07

    Registered record
    Registry ID
    NCT01146288
    Conditions
    Obesity-induced Hyperfiltration
    Interventions
    Furosemide first, then Acetazolamide; Acetazolamide first, then Furosemide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-07
    Completion
    2014-05
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity-induced Hyperfiltration
    InterventionFurosemide first, then Acetazolamide; Acetazolamide first, then Furosemide
    PhaseNot applicable
    Registry statusCompleted

  • Assessment of Renal Physiology by Magnetic Resonance Imaging (MRI) in Normal Volunteers

    NCT00936416 · start 2010-01

    Registered record
    Registry ID
    NCT00936416
    Conditions
    Glomerular Filtration Rate; Renal Blood Flow
    Interventions
    Inulin and PAH clearance and MRI
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-01
    Completion
    2011-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlomerular Filtration Rate; Renal Blood Flow
    InterventionInulin and PAH clearance and MRI
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Furosemide on Obesity-induced Glomerular Hyperfiltration

    NCT00962286 · start 2009-09

    Registered record
    Registry ID
    NCT00962286
    Conditions
    Obesity-induced Hyperfiltration
    Interventions
    Furosemide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2009-09
    Completion
    2010-07
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity-induced Hyperfiltration
    InterventionFurosemide
    PhaseNot applicable
    Registry statusTerminated

  • Vascular Dysfunction in Diabetes: Genes and Hormones

    NCT01511042 · start 1999-12

    Registered record
    Registry ID
    NCT01511042
    Conditions
    Diabetes Mellitus
    Interventions
    Para-aminohippuric Acid; Angiotensin II; Norepinephrine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    1999-12
    Completion
    2020-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus
    InterventionPara-aminohippuric Acid; Angiotensin II; Norepinephrine
    PhaseNot recorded
    Registry statusTerminated

  • Genetic Mechanisms in Human Hypertension

    NCT01456208 · start 1999-10

    Registered record
    Registry ID
    NCT01456208
    Conditions
    Hypertension
    Interventions
    Para-aminohippuric Acid; Angiotensin II; Norepinephrine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    1999-10
    Completion
    2020-06
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionPara-aminohippuric Acid; Angiotensin II; Norepinephrine
    PhaseNot recorded
    Registry statusTerminated